Trump announces 100% chip tariff as Apple ups U.S. investment
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), a biotechnology company specializing in longevity research, reported progress in its therapeutic development aimed at combating age-related diseases. The company’s MASH study has moved closer to the pre-IND phase of preclinical development, following positive feedback from the FDA.
In 2024, Genflow initiated collaborations with renowned researchers and laboratories, securing two non-diluting, non-reimbursable research grants. This bolstered its financial position, with £1.4 million raised through grants and equity fundraising. The Annual Report, detailing the final results for the year ended December 31, 2024, is available on the company’s website.
Genflow, the first longevity biotech company to list in Europe, is focused on gene therapies targeting metabolic dysfunction-associated steatohepatitis (MASH) and Werner Syndrome. The company has partnered with Exothera SA for GMP manufacturing of clinical lots and received a €4,026,525 non-dilutive financial support package from the Wallonia region, subject to meeting certain conditions.
The company’s research programs include a sarcopenia research program with Revatis SA and an exosome-mRNA project with EXO Biologics, both supported by the Government of Wallonia in Belgium. Additionally, Genflow has entered into a strategic partnership with Heureka Labs, Inc. to utilize AI technology for genomic data analysis.
As of December 31, 2024, the Group had cash reserves of £278,682 and was debt-free. The Group’s administration expenses for 2024 totaled £1,907,706, with £320,471 recognized as grant income related to the research grants.
Genflow plans to continue advancing its research programs and launch a clinical trial focused on aged dogs, as well as a new ophthalmology development program targeting ocular problems. The company aims to complete and analyze the results of the clinical trial in aged dogs by the end of 2025.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.